Pasquali C, Sperti C, D'Andrea A A, Bonadimani B, Del Favero G, Petrin P, Pedrazzoli S
Pancreas. 1987;2(1):34-7. doi: 10.1097/00006676-198701000-00005.
The diagnostic value of the tumor-associated antigens Ca 19-9 and Ca 12-5 was tested in 130 subjects (38 healthy controls, 37 carcinomas of the pancreas, 23 chronic pancreatitis, 23 extrapancreatic gastrointestinal cancers, 9 endocrine pancreatic tumors). Ca 19-9 levels above 37 U/ml were obtained in 67.6% and Ca 12-5 levels above 39 U/ml in 45.9% of carcinomas of the pancreas, 4.3 and 8.7%, respectively, of chronic pancreatis, 21.7 and 17.4% of extrapancreatic gastrointestinal tumors, and 0 and 11.1% of endocrine pancreatic tumors and in none of the healthy controls. Results of preoperative determination of Ca 19-9 and Ca 12-5 gave a sensitivity of 67.6 and 45.9%, a specificity of 91.8 and 90.9%, a predictive value of a positive test of 80.6 and 70.8%. When elevation of both antigens was required, sensitivity decreased to 32.4% but specificity rose to 97.3%. All but one of the pancreatic cancer patients were at stage 3 and 4. The only patient with pancreatic cancer in stage 1 had normal levels of both markers. Ca 19-9 and Ca 12-5, whether alone or associated, represent a good diagnostic test for differentiating pancreatic cancer from chronic pancreatitis. Due to the low sensitivity of both markers, the tests are of limited value when any other diagnostic evidence of pancreatic cancer is absent.
对130名受试者（38名健康对照者、37例胰腺癌患者、23例慢性胰腺炎患者、23例胰腺外胃肠道癌患者、9例胰腺内分泌肿瘤患者）检测了肿瘤相关抗原Ca 19-9和Ca 12-5的诊断价值。胰腺癌患者中，67.6%的患者Ca 19-9水平高于37 U/ml，45.9%的患者Ca 12-5水平高于39 U/ml；慢性胰腺炎患者中，这一比例分别为4.3%和8.7%；胰腺外胃肠道肿瘤患者中，分别为21.7%和17.4%；胰腺内分泌肿瘤患者中，分别为0和11.1%；健康对照者中均无升高。术前测定Ca 19-9和Ca 12-5的结果显示，敏感性分别为67.6%和45.9%，特异性分别为91.8%和90.9%，阳性试验预测值分别为80.6%和70.8%。若要求两种抗原均升高，则敏感性降至32.4%，但特异性升至97.3%。除1例患者外，所有胰腺癌患者均处于3期和4期。唯一1例1期胰腺癌患者的两种标志物水平均正常。Ca 19-9和Ca 12-5单独或联合使用时，都是鉴别胰腺癌和慢性胰腺炎的良好诊断检测方法。由于这两种标志物的敏感性较低，在缺乏胰腺癌其他诊断证据时，这些检测的价值有限。
